Delivery Order SPE2DB22D3401-SPE2DB25FT5SS
- Not listed
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $5,400.47 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $47,262.06 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete openly for...
- The Defense Logistics Agency awarded a $12,356.56 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price contract, which received no set-aside designation, leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $66,460.68 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and carries an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this delivery order, with performance taking place at the company's Conshohocken...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $15.5K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5SSDelivery Order
The Defense Logistics Agency (DLA) awarded a $21,260.48 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a single shipment of the biologic medication to support federal medical procurement needs. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for the Defense Health Agency and military healthcare systems, supplying a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive federal contract portfolio demonstrates its capability to fulfill both routine and specialized medical supply requirements across the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 8/18/25 |